èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Adaptimmune Therapeutics plc ã¯ãäž»ã«ç±³åœãšè±åœã®åºåœ¢è
«çæ£è
ã«æ°ãã现èçæ³ãæäŸããããšã«éç¹ã眮ããŠããŸããå瀟ã®ç¹å®ã®ãããã匷åèŠªåæ§åå®¹äœ (SPEAR) T 现èãã©ãããã©ãŒã ã«ãããããã®ã¿ãŒã²ãããç¹å®ã§ããŸããå瀟㯠ADP-A2M4 ãéçºããŠãããããã¯æ»èèè
«ããã³ç²æ¶²å圢现èèèªèè
« (MRCLS) ã®é©å¿çã§ SPEARHEAD-1 ãšã®ç¬¬ II çžèšåºè©Šéšäžãé é žéšããã®æ£è
ã§ SPEARHEAD-2 ãšã®ç¬¬ II çžèšåºè©Šéšäžãå°¿è·¯äžç®ãããé»è²è
«ãé é žéšãããåµå·£ãããéå°çްèèºãããé£éããããã³èãããæ»èèè
«ãMRCLS ããã®ç¬¬ I çžèšåºè©Šéšäžã§ããå瀟ã¯ãŸããè现èããã®ç¬¬ I çžèšåºè©Šéšäžã® ADP-A2AFP ãéçºããŠããŸãããŸããèºãããèé£éãããé é žéšãããèè±ããã®æ£è
ã®æ²»çã«çŠç¹ãåœãŠã SPEAR T 现èã®ãã§ãŒãº I èšåºè©Šéšäžã® ADP-A2M4CD8 ããããŸããå瀟㯠GSK ãšã®ååããã³ã©ã€ã»ã³ã¹å¥çŽãNoile-Immune Biotech Inc.ãAlpine Immune Sciences, Inc.ããã³ããŒã¯ã®åœç«ããå
ç«çæ³ã»ã³ã¿ãŒãšã®ãµãŒãããŒãã£ååãMD ã¢ã³ããŒãœã³ããã»ã³ã¿ãŒãšã®æŠç¥çææºå¥çŽãUniversal Cells, Inc. ãšã®å
±åéçºããã³å
±ååååå¥çŽãç· çµããŠããŸããAdaptimmune Therapeutics plc ã¯ãŸããGenentech, Inc. ãšæŠç¥çååããã³ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠãããããŸããŸãªè
«çåŠã®é©å¿çãæ²»çããããã®å皮现èçæ³ã®éçºãšåååãè¡ã£ãŠããŸããå瀟㯠2008 幎ã«èšç«ãããè±åœã¢ãã³ãã³ã«æ¬ç€Ÿã眮ããŠããŸãã